A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

An Open-label, Multicenter, Global Phase 2 Basket Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of STI-3031 in Patients With Selected Relapsed or Refractory Malignancies.

This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.

Study Overview

• Status: Withdrawn
• Conditions: Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Peripheral T Cell Lymphoma; Extranodal NK T Cell Lymphoma, Nasal
• Intervention / Treatment: Biological: STI-3031

Detailed Description

This is an open-label, multicenter, global Phase 2 basket study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of STI-3031 in patients with selected relapsed or refractory (R/R) malignancies. The study will be conducted as separate Phase 2, single arm substudies for each of the indications below:

• Extranodal NK/T-cell lymphoma (ENKTL)
• Peripheral T-cell lymphomas (PTCL)
• Diffuse large B-cell lymphoma (DLBCL) with PD-L1 gene translocation, copy gain, amplification, polysomy detectable by a fluorescence in situ hybridization (FISH) assay or Epstein-Barr virus positivity (EBV+) as assessed by EBV-encoded small RNA (EBER) testing
• Biliary tract cancers (BTC) (intrahepatic cholangiocarcinoma), extrahepatic cholangiocarcinoma or gallbladder cancer)

All participants will receive the study intervention, STI-3031.

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Mike Royal, MD JD MBA; Phone Number: 4146 858-203-4100; Email: mroyal@sorrentotherapeutics.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Documented histologically confirmed diagnoses of Extranodal NK/T-cell lymphoma, Peripheral T-cell lymphoma, Diffuse Large B-cell lymphoma (with a PD-L1 gene abnormality or Epstein-Barr virus positivity, or biliary tract cancer.

• Prior treatment:

  • Extranodal NK/T-cell lymphoma: Must have received at least 1 previous line of systemic therapy including an asparaginase-based regimen.
  • Peripheral T-cell lymphoma: must have received at least 1 previous line of systemic multi-agent chemotherapy. Participants with anaplastic large cell lymphoma (ALCL) must have received brentuximab vedotin
  • Diffuse Large B-cell lymphoma: Must have received at least 2 previous lines of systemic therapy including an anti-CD20 antibody
  • Biliary Tract Cancer: Must have received at least 1 previous line of systemic therapy including gemcitabine with or without platinum
• Documented disease progression during or after the last therapy
• If not previously treated with transplant, Investigator considers the participant ineligible for transplant
• Measurable disease
• Adult age (as defined by respective country) at time of signing informed consent form (ICF)
• Must be able to understand the nature of the study and provide a signed and dated, written ICF prior to any study-specific procedures, sample collections and analyses
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
• Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment and radiopharmaceuticals are permitted if more than 8 weeks have elapsed since the end of treatment
• At least 14 days or 5 half-lives must have elapsed since the last chemotherapy, immunotherapy, biological or investigational therapy, and have recovered from toxicities associated with such treatment to < Grade 2
• Adequate hematologic, renal and hepatic function
• Females of childbearing potential (FCBP) must agree to use a reliable form of contraceptive during the study treatment period and for at least 90 days following the last dose of study intervention
• Male participants must agree to use barrier contraception (i.e., condoms) for the duration of the study and for at least 90 days after the last dose of study intervention
• Predicted life expectancy of at least 16 weeks

Exclusion Criteria:

• Current participation in another therapeutic clinical trial
• Prior treatment with an anti-PD-L1 or anti-PD-1 antibody
• Patients with symptomatic central nervous system (CNS) metastases unless considered adequately treated and controlled for at least 2 weeks
• Prior hematopoietic stem cell transplantation
• History of other previous cancer that would interfere with the determination of safety or efficacy
• Any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for participants with vitiligo, hormone replacement therapy for stable thyroid diseases and Type 1 diabetes mellitus
• Apparent active or latent tuberculosis (TB) infection
• Seropositive for or have active infection with hepatitis C virus (HCV), unless HCV viral load is below the limit of quantification and participant is on concurrent viral suppressive therapy
• Seropositive for or have active viral infection with hepatitis B virus (HBV), unless HBV viral load is below the limit of quantification and participant is on concurrent viral suppressive therapy

• Seropositive for or active viral infection with HIV, unless the following are met:

  • CD4+ T-cell (CD4+) counts ≥ 350 cells/uL; and
  • Participant has been on established antiretroviral therapy (ART) for at least 4 weeks prior to screening and have HIV viral load < 400 copies/mL; and
  • Participant has not had acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the past 12 months prior to screening
• Active infection (viral, bacterial, or fungal) requiring intravenous (IV) systemic therapy within 14 days
• Evidence of bleeding diathesis or coagulopathy.
• Significant proteinuria
• Conditions requiring chronic steroid use (> 10 mg/day of prednisone or equivalent).
• Recent history of attenuated viral vaccination within 30 days prior to the first dose of study intervention
• Herbal preparations/medications are not allowed throughout the treatment period unless first discussed with and approved by the Medical Monitor
• History of severe hypersensitivity reactions to other monoclonal antibodies or known hypersensitivity to the study intervention or its excipients.
• Known current drug or alcohol abuse
• Major surgical procedures ≤ 28 days prior to the first dose of study intervention, or minor surgical procedures ≤7 days prior to the first dose of study intervention
• Pregnant or lactating

• Any of the following cardiac diseases currently or within the last 6 months:

  • QT interval corrected using Fridericia's formula >450 milliseconds in men and > 470 milliseconds in women (up to 480 milliseconds may be allowed after discussion between the Investigator and the Medical Monitor).
  • Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
  • Unstable angina pectoris
  • Congestive heart failure (New York Heart Association ≥ Grade 2)
  • Acute myocardial infarction
  • Clinically significant conduction abnormality not controlled with pacemaker or medication
  • Significant ventricular or supraventricular arrhythmias (Participants with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible.)
• Underlying medical conditions that, in the opinion of the investigator and/or medical monitor, will render the administration of study drug hazardous or obscure the interpretation of safety or efficacy results

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Extranodal NK/T-cell lymphoma (ENKTL); Intravenous STI-3031 (anti-PD-L1 antibody)	Biological: STI-3031; anti-PD-L1 antibody; Other Names: IMC-001
Experimental: Peripheral T-cell lymphomas (PTCL); Intravenous STI-3031 (anti-PD-L1 antibody)	Biological: STI-3031; anti-PD-L1 antibody; Other Names: IMC-001
Experimental: Diffuse large B-cell lymphoma (DLBCL); Intravenous STI-3031 (anti-PD-L1 antibody)	Biological: STI-3031; anti-PD-L1 antibody; Other Names: IMC-001
Experimental: Biliary tract cancers (BTC); Intravenous STI-3031 (anti-PD-L1 antibody)	Biological: STI-3031; anti-PD-L1 antibody; Other Names: IMC-001

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate	Percentage of participants achieving a Complete Response (CR) or Partial Response (PR) at any time during the study as assessed by an Independent Response Committee (IRC) per the Lugano criteria with LYRIC modification or RECIST 1.1	Approximately 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate by treating physician	Percentage of participants achieving a CR or PR at any time during the study as assessed by the Investigator per the Lugano criteria with LYRIC modification or RECIST 1.1	Approximately 24 months
Duration of Response	Time from the first documentation of response (CR or PR) to the first documentation of progressive disease (PD) as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1	Approximately 24 months
Complete Response Rate	Percentage of participants achieving a CR at any time during the study as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1	Approximately 24 months
Duration of Complete Response Rate	Time from the first documentation of CR to the first documentation of PD as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1	Approximately 24 months
Progressive-free survival	Time from enrollment until PD or death as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1	Approximately 24 months
12-month Progressive-free survival	Percentage of participants without PD or death at 12 months after their first dose of study intervention as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1	Approximately 30 months (18 months for enrollment plus 12 months follow-up for the last participant enrolled)
Event free survival	Time from enrollment to PD, death, or start of new treatment as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1	Approximately 24 months
Area Under the Curve (AUC) of the blood levels of STI-3031	Measure the actual body exposure to STI-3031	Approximately 24 months
Maximum Plasma Concentration (Cmax) of STI-3031	Measure the maximum (or peak) blood concentration of STI-3031	Approximately 24 months
Time of Maximum concentration observed (Tmax) of STI-3031	Measure the is the time at which the maximum blood concentration of STI-3031 is observed	Approximately 24 months
Half-life (t1/2) of STI-3031	Measure the time it takes for the concentration of the drug in the blood to be reduced by 50%	Approximately 24 months
Immunogenicity	Incidence of anti-drug antibody (ADA) (serum titers of anti-STI-3031 antibodies) and correlation with exposure and activity	Approximately 24 months
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of STI-3031	Terms, frequency, severity and seriousness of adverse events (AEs) and relationship of AEs to STI-3031 the actual body exposure to drug after administration	Approximately 24 months

Collaborators and Investigators

• Sponsor: Sorrento Therapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Anticipated): March 1, 2023
• Primary Completion (Anticipated): January 1, 2024
• Study Completion (Anticipated): July 1, 2024

Study Registration Dates

• First Submitted: June 24, 2019
• First Submitted That Met QC Criteria: June 26, 2019
• First Posted (Actual): June 27, 2019

Study Record Updates

• Last Update Posted (Actual): May 1, 2023
• Last Update Submitted That Met QC Criteria: April 27, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: DLBCL; PTCL; cholangiocarcinoma; PD-L1; relapsed; refractory; anti-PD-L1 antibody; T/NK-cell; NK/T-cell; ENKTL; peripheral T-cell; gall bladder cancer
• Additional Relevant MeSH Terms: Digestive System Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Neoplasms by Site; Digestive System Neoplasms; Biliary Tract Diseases; Lymphoma, B-Cell; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Lymphoma, Extranodal NK-T-Cell; Biliary Tract Neoplasms
• Other Study ID Numbers: STI-3031-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No